Skip to main content
Article
Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma
Urology (1993)
  • McClellan M. Walther, From the Surgery Branch and the Biostatistics and Data Management Sections, Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland, USA
  • Richard B. Alexander, From the Surgery Branch and the Biostatistics and Data Management Sections, Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland, USA
  • Gary H. Weiss, From the Surgery Branch and the Biostatistics and Data Management Sections, Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland, USA
  • David Venzon, From the Surgery Branch and the Biostatistics and Data Management Sections, Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland, USA
  • Arlene Berman, From the Surgery Branch and the Biostatistics and Data Management Sections, Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland, USA
  • Harvey I. Pass, From the Surgery Branch and the Biostatistics and Data Management Sections, Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland, USA
  • W.Marston Linehan, From the Surgery Branch and the Biostatistics and Data Management Sections, Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland, USA
  • Steven A. Rosenberg, From the Surgery Branch and the Biostatistics and Data Management Sections, Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland, USA
Publication Date
September 1, 1993
DOI
10.1016/S0022-5347(01)64091-6
Citation Information
McClellan M. Walther, Richard B. Alexander, Gary H. Weiss, David Venzon, et al.. "Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma" Urology Vol. 42 Iss. 3 (1993) p. 250 - 257
Available at: http://works.bepress.com/richard-alexanderMD/45/